management should include good coordination of care with Family medicine, Transplant/nephrology team and social services for efficacious and successful management of patient.

**FUNDING ACKNOWLEDGEMENTS:** No funding.

### ABSTRACT 158

**Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study**

Karen E. Anderson, MD1; Mat D. Davis, PhD2; Stewart A. Factor, DO3; Robert A. Hauser, MD, MBA4; L. Fredrik Jaraskog, MD5; Joohi Jimenez-Shahed, MD5; Rajeev Kumar, MD, FRCPC6; William G. Ondo, MD7; and Hubert H. Fernandez, MD10

1 Georgetown University, Washington, District of Columbia, USA
2 Teva Pharmaceutical Industries, Frazer, Pennsylvania, USA
3 Emory University, Atlanta, Georgia, USA
4 University of South Florida Parkinson’s Disease and Movement Disorders Center, Tampa, Florida, USA
5 University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
6 Baylor College of Medicine, Houston, Texas, USA
7 Rocky Mountain Movement Disorders Center, Englewood, Colorado, USA
8 University Clinical Center of Silesian Medical University, Katowice, Poland
9 Methodist Neurological Institute, Houston, Texas, USA
10 Cleveland Clinic, Cleveland, Ohio, USA

**ABSTRACT:** Introduction: In the 12-week ARM-TD and AIM-TD studies, deutetrabenazine showed clinically significant improvements in Abnormal Involuntary Movement Scale (AIMS) scores at Week 12 compared with placebo, and was generally well tolerated.

**OBJECTIVE:** To evaluate the long-term safety/tolerability and efficacy of deutetrabenazine in patients with TD. Week 54 open-label results are reported in this interim analysis.

**METHODS:** Patients with TD who completed ARM-TD or AIM-TD were included in this open-label, single-arm extension study, in which all patients restarted/started deutetrabenazine 12 mg/day, titrating up to a maximum total daily dose of 48 mg/day based on dyskinesia control and tolerability. The study comprised a 6-week titration period and a long-term maintenance phase. Safety measures included incidence of adverse events (AEs), serious AEs (SAEs), drug-related AEs, and AEs leading to withdrawal, dose reduction, or dose suspension. This analysis reports results up to Week 54.

**RESULTS:** 304 patients enrolled in the extension study. There were 215 patient-years of exposure in this analysis, and exposure-adjusted incidence rates (EAIRs) of AEs (incidence/patient-years) were comparable to or lower than those observed with short-term deutetrabenazine treatment and placebo. The frequency of SAEs (EAIR 0.14) was similar to rates observed with short-term placebo (EAIR 0.33) and deutetrabenazine (EAIR range 0.06–0.33) treatment. AEs leading to study discontinuation (EAIR 0.08), dose reduction (EAIR 0.17), and dose suspension (EAIR 0.09) were uncommon.

**CONCLUSIONS:** Long-term treatment with deutetrabenazine was generally safe and well tolerated in patients with TD, and did not result in cumulative toxicity.

Presented at: The American Psychiatric Association 2017 Annual Meeting; May 20–24, 2017; San Diego, California, USA.

**FUNDING ACKNOWLEDGEMENTS:** This study was funded by Teva Pharmaceutical Industries, Petach Tikva, Israel.

### ABSTRACT 160

**Optimizing TMS Treatment for Depression - The 19 Minute Dash™ Protocol**

Miriam Mina1; David G. Brock, MD2; Alvaro Pascual-Leone, MD, PhD3; and Mark A. Demitrak, MD4

1 Neuronetics, Inc., Malvern, PA
2 no affiliation, Ambler, PA
3 Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
4 Axovant Sciences, Inc, New York, NY

**ABSTRACT:** Title: Optimizing TMS treatment for Depression - The 19 Minute Dash™ protocol

**OBJECTIVE:** NeuroStar transcranial magnetic stimulation (TMS) is an effective treatment for patients with major depressive disorder. Due to the treatment session duration, a reduced treatment time would promote patients’ comfort and convenience. Also, shorter treatment sessions of retained efficacy and safety would increase access to treatment. This reduction could be accomplished by decreasing the time between TMS pulse sequences, the intertrain interval (ITI).

**METHODS:** Meta-analysis of TMS delivered using varying treatment parameters, particularly the ratio of train